Faricimab
- Generic Name
- Faricimab
- Brand Names
- Vabysmo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1607793-29-2
- Unique Ingredient Identifier
- QC4F7FKK7I
- Background
Retinal vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization (NV). Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of retinal NV, and many currently approved RVD therapies such as...
- Indication
Faricimab is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME).
- Associated Conditions
- Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD), Visual Impairment
- Associated Therapies
- -
Govt adds drug for disease that can impact eyes to PBS roster
Australians with Fabry disease now have cheaper access to Migalastat (Galafold) through PBS, benefiting 65 patients annually. Eligible patients will pay a maximum of $31.60 per script, or $7.70 with a concession card.
FDA Approves Genentech’s Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss
FDA approves Genentech's Vabysmo Prefilled Syringe (PFS) for wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), affecting nearly 3 million people in the U.S. Vabysmo PFS, a bispecific antibody, offers a ready-to-use format, enhancing treatment simplicity and effectiveness.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath